| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 85 | 2024 | 5574 | 5.360 |
Why?
|
| Lung Neoplasms | 95 | 2024 | 12033 | 3.970 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 83 | 2023 | 16689 | 1.860 |
Why?
|
| Quinazolines | 14 | 2022 | 956 | 1.340 |
Why?
|
| Niacinamide | 9 | 2013 | 428 | 1.150 |
Why?
|
| Benzenesulfonates | 4 | 2011 | 196 | 1.030 |
Why?
|
| Breast Neoplasms | 149 | 2017 | 16215 | 1.010 |
Why?
|
| Carboplatin | 17 | 2019 | 880 | 1.010 |
Why?
|
| Carcinoma, Squamous Cell | 21 | 2021 | 5593 | 0.990 |
Why?
|
| Head and Neck Neoplasms | 16 | 2023 | 4147 | 0.980 |
Why?
|
| Antineoplastic Agents | 73 | 2018 | 14617 | 0.940 |
Why?
|
| ErbB Receptors | 19 | 2022 | 2375 | 0.920 |
Why?
|
| Neoplasm Recurrence, Local | 29 | 2023 | 10400 | 0.850 |
Why?
|
| Antineoplastic Agents, Immunological | 10 | 2021 | 1335 | 0.830 |
Why?
|
| Angiogenesis Inhibitors | 8 | 2013 | 1269 | 0.830 |
Why?
|
| Paclitaxel | 17 | 2019 | 2101 | 0.810 |
Why?
|
| Indoles | 6 | 2013 | 1028 | 0.750 |
Why?
|
| Aged | 176 | 2024 | 73333 | 0.730 |
Why?
|
| Pyridines | 5 | 2020 | 1313 | 0.690 |
Why?
|
| Protein Kinase Inhibitors | 14 | 2022 | 4961 | 0.680 |
Why?
|
| Biomarkers, Tumor | 17 | 2021 | 10708 | 0.680 |
Why?
|
| Carcinoma, Large Cell | 4 | 2016 | 98 | 0.680 |
Why?
|
| Middle Aged | 197 | 2024 | 90352 | 0.660 |
Why?
|
| Humans | 300 | 2024 | 270740 | 0.650 |
Why?
|
| Antigens, Neoplasm | 3 | 2023 | 1580 | 0.630 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 5 | 2013 | 361 | 0.590 |
Why?
|
| Antibodies, Monoclonal, Humanized | 15 | 2023 | 3409 | 0.580 |
Why?
|
| Phenylurea Compounds | 6 | 2013 | 600 | 0.580 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2015 | 161 | 0.580 |
Why?
|
| Cetuximab | 14 | 2023 | 474 | 0.570 |
Why?
|
| Female | 226 | 2024 | 148940 | 0.560 |
Why?
|
| Erlotinib Hydrochloride | 11 | 2015 | 398 | 0.550 |
Why?
|
| Taxoids | 5 | 2017 | 1015 | 0.540 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2022 | 1137 | 0.540 |
Why?
|
| Neoplasm Metastasis | 77 | 2020 | 5315 | 0.540 |
Why?
|
| Disease-Free Survival | 22 | 2017 | 10265 | 0.520 |
Why?
|
| Carcinoma, Adenoid Cystic | 2 | 2023 | 444 | 0.520 |
Why?
|
| Adult | 165 | 2023 | 82040 | 0.510 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2023 | 1840 | 0.510 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2015 | 46 | 0.490 |
Why?
|
| Neoplasm Staging | 31 | 2023 | 14012 | 0.490 |
Why?
|
| Antibodies, Monoclonal | 13 | 2024 | 4481 | 0.480 |
Why?
|
| Male | 105 | 2024 | 128315 | 0.480 |
Why?
|
| Platinum | 4 | 2023 | 142 | 0.480 |
Why?
|
| B7-H1 Antigen | 10 | 2024 | 1089 | 0.480 |
Why?
|
| Immunotherapy | 15 | 2024 | 3557 | 0.470 |
Why?
|
| Survival Analysis | 18 | 2018 | 9292 | 0.460 |
Why?
|
| Immunoconjugates | 3 | 2023 | 314 | 0.460 |
Why?
|
| Pemetrexed | 4 | 2023 | 100 | 0.460 |
Why?
|
| Pyrimidinones | 2 | 2016 | 318 | 0.450 |
Why?
|
| Molecular Targeted Therapy | 6 | 2013 | 2399 | 0.440 |
Why?
|
| Pyridones | 2 | 2016 | 360 | 0.440 |
Why?
|
| Antineoplastic Agents, Phytogenic | 6 | 2015 | 894 | 0.430 |
Why?
|
| Proto-Oncogene Proteins c-met | 3 | 2013 | 426 | 0.430 |
Why?
|
| Pyrroles | 3 | 2013 | 588 | 0.420 |
Why?
|
| Aged, 80 and over | 40 | 2021 | 30998 | 0.420 |
Why?
|
| Maximum Tolerated Dose | 11 | 2023 | 1322 | 0.420 |
Why?
|
| Oncogene Protein v-akt | 1 | 2012 | 101 | 0.420 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2015 | 497 | 0.410 |
Why?
|
| Treatment Outcome | 37 | 2023 | 33737 | 0.400 |
Why?
|
| Doxorubicin | 57 | 1987 | 3145 | 0.400 |
Why?
|
| Ipilimumab | 5 | 2023 | 764 | 0.390 |
Why?
|
| T-Lymphocytes | 3 | 2024 | 3949 | 0.390 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 5 | 2023 | 1402 | 0.380 |
Why?
|
| Receptors, Somatomedin | 1 | 2011 | 72 | 0.380 |
Why?
|
| Mitomycins | 12 | 1985 | 52 | 0.380 |
Why?
|
| Neoplasms | 22 | 2023 | 15927 | 0.380 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2023 | 1710 | 0.370 |
Why?
|
| Quinolines | 2 | 2012 | 402 | 0.370 |
Why?
|
| Neoplasm Proteins | 2 | 2023 | 3345 | 0.370 |
Why?
|
| Mutation | 15 | 2024 | 15912 | 0.360 |
Why?
|
| Drug Administration Schedule | 27 | 2020 | 3530 | 0.350 |
Why?
|
| Prognosis | 52 | 2021 | 22505 | 0.350 |
Why?
|
| Anilides | 1 | 2012 | 295 | 0.340 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2012 | 1002 | 0.340 |
Why?
|
| Fluorouracil | 47 | 2019 | 1990 | 0.340 |
Why?
|
| BCG Vaccine | 28 | 1986 | 428 | 0.330 |
Why?
|
| Dose-Response Relationship, Drug | 19 | 2018 | 5056 | 0.310 |
Why?
|
| Drug Resistance, Neoplasm | 11 | 2024 | 5408 | 0.310 |
Why?
|
| Adenocarcinoma | 11 | 2016 | 7914 | 0.310 |
Why?
|
| Tamoxifen | 14 | 1997 | 875 | 0.310 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2008 | 246 | 0.300 |
Why?
|
| Survival Rate | 19 | 2021 | 12541 | 0.290 |
Why?
|
| Thrombocytopenia | 9 | 2023 | 870 | 0.290 |
Why?
|
| Circulating Tumor DNA | 2 | 2021 | 274 | 0.280 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 2 | 2024 | 118 | 0.280 |
Why?
|
| Cyclophosphamide | 49 | 1997 | 3245 | 0.280 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2012 | 1563 | 0.280 |
Why?
|
| GPI-Linked Proteins | 2 | 2020 | 232 | 0.270 |
Why?
|
| Follow-Up Studies | 27 | 2021 | 15218 | 0.270 |
Why?
|
| Oligonucleotides | 3 | 2011 | 242 | 0.250 |
Why?
|
| Pyridazines | 2 | 2019 | 324 | 0.250 |
Why?
|
| Hydroxamic Acids | 1 | 2007 | 454 | 0.240 |
Why?
|
| Bone Neoplasms | 11 | 2012 | 2665 | 0.240 |
Why?
|
| Clinical Trials as Topic | 23 | 2020 | 3844 | 0.240 |
Why?
|
| Bevacizumab | 6 | 2023 | 967 | 0.240 |
Why?
|
| Vinblastine | 12 | 2002 | 462 | 0.240 |
Why?
|
| Chemoradiotherapy | 7 | 2022 | 2027 | 0.230 |
Why?
|
| Time Factors | 39 | 2018 | 13006 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2018 | 6256 | 0.230 |
Why?
|
| Maytansine | 2 | 2022 | 40 | 0.220 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2007 | 617 | 0.220 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2023 | 417 | 0.220 |
Why?
|
| Mucositis | 1 | 2023 | 149 | 0.210 |
Why?
|
| Liver Neoplasms | 5 | 2018 | 4821 | 0.210 |
Why?
|
| Network Meta-Analysis | 1 | 2023 | 56 | 0.210 |
Why?
|
| Double-Blind Method | 5 | 2022 | 2580 | 0.210 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2011 | 1580 | 0.210 |
Why?
|
| Bayes Theorem | 3 | 2023 | 1060 | 0.200 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 2 | 2013 | 109 | 0.200 |
Why?
|
| Combined Modality Therapy | 20 | 2023 | 9039 | 0.200 |
Why?
|
| Exons | 3 | 2022 | 1383 | 0.200 |
Why?
|
| Genes, erbB | 1 | 2021 | 27 | 0.190 |
Why?
|
| Methotrexate | 23 | 2017 | 1025 | 0.190 |
Why?
|
| Lymphopenia | 1 | 2023 | 211 | 0.190 |
Why?
|
| Administration, Oral | 7 | 2015 | 1608 | 0.190 |
Why?
|
| Tissue Distribution | 3 | 2012 | 927 | 0.180 |
Why?
|
| Arthritis | 1 | 2022 | 148 | 0.180 |
Why?
|
| Piperazines | 3 | 2019 | 2145 | 0.180 |
Why?
|
| Lymphocyte Depletion | 1 | 2022 | 316 | 0.180 |
Why?
|
| Bone Marrow | 12 | 1997 | 2441 | 0.180 |
Why?
|
| CTLA-4 Antigen | 1 | 2024 | 678 | 0.180 |
Why?
|
| Bone Marrow Transplantation | 4 | 1997 | 1757 | 0.180 |
Why?
|
| Genetic Engineering | 1 | 2022 | 295 | 0.170 |
Why?
|
| Drug Therapy, Combination | 49 | 1992 | 2345 | 0.170 |
Why?
|
| Skin Neoplasms | 4 | 2021 | 4895 | 0.170 |
Why?
|
| Radiology, Interventional | 1 | 2020 | 142 | 0.160 |
Why?
|
| Aminoglutethimide | 3 | 1984 | 13 | 0.160 |
Why?
|
| Hormones | 5 | 1985 | 285 | 0.160 |
Why?
|
| Carcinoma | 11 | 2007 | 2610 | 0.160 |
Why?
|
| Consolidation Chemotherapy | 1 | 2019 | 153 | 0.160 |
Why?
|
| Receptor, ErbB-3 | 2 | 2017 | 126 | 0.150 |
Why?
|
| Drug Evaluation | 29 | 1987 | 432 | 0.150 |
Why?
|
| Receptors, Estrogen | 10 | 2012 | 2170 | 0.150 |
Why?
|
| Signal Transduction | 5 | 2015 | 12103 | 0.150 |
Why?
|
| Receptor, ErbB-2 | 5 | 2021 | 2651 | 0.140 |
Why?
|
| Disease Progression | 8 | 2020 | 6867 | 0.140 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2014 | 2617 | 0.140 |
Why?
|
| Neoplasms, Hormone-Dependent | 4 | 1985 | 347 | 0.140 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2010 | 770 | 0.140 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 3 | 2011 | 73 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 3 | 2024 | 5231 | 0.130 |
Why?
|
| HLA Antigens | 1 | 2019 | 594 | 0.130 |
Why?
|
| Drug Delivery Systems | 2 | 2011 | 661 | 0.130 |
Why?
|
| Nausea | 8 | 2009 | 539 | 0.130 |
Why?
|
| Papillomaviridae | 1 | 2019 | 636 | 0.130 |
Why?
|
| Proportional Hazards Models | 6 | 2018 | 5101 | 0.130 |
Why?
|
| Image-Guided Biopsy | 2 | 2020 | 336 | 0.130 |
Why?
|
| ras Proteins | 3 | 2014 | 804 | 0.120 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2017 | 690 | 0.120 |
Why?
|
| Medroxyprogesterone | 2 | 1985 | 13 | 0.120 |
Why?
|
| Gene Frequency | 2 | 2021 | 1246 | 0.120 |
Why?
|
| Sesquiterpenes | 3 | 2004 | 70 | 0.120 |
Why?
|
| Megestrol | 3 | 1983 | 15 | 0.120 |
Why?
|
| src-Family Kinases | 2 | 2014 | 487 | 0.120 |
Why?
|
| Cisplatin | 8 | 2019 | 2497 | 0.110 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2014 | 529 | 0.110 |
Why?
|
| Patient Selection | 3 | 2012 | 2025 | 0.110 |
Why?
|
| Radiosurgery | 1 | 2023 | 1383 | 0.110 |
Why?
|
| Eyelid Neoplasms | 2 | 2008 | 193 | 0.110 |
Why?
|
| Hematopoietic Stem Cells | 3 | 1997 | 1367 | 0.110 |
Why?
|
| Camptothecin | 3 | 2010 | 540 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2018 | 2650 | 0.110 |
Why?
|
| Retrospective Studies | 13 | 2023 | 39890 | 0.110 |
Why?
|
| Survival | 1 | 2013 | 183 | 0.110 |
Why?
|
| Dasatinib | 2 | 2014 | 881 | 0.110 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2011 | 191 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2021 | 1388 | 0.100 |
Why?
|
| Carcinoembryonic Antigen | 3 | 1983 | 231 | 0.100 |
Why?
|
| Anorexia | 2 | 2017 | 147 | 0.100 |
Why?
|
| Gene Dosage | 2 | 2012 | 823 | 0.100 |
Why?
|
| Translocation, Genetic | 1 | 2018 | 1286 | 0.100 |
Why?
|
| Remission Induction | 3 | 2015 | 3656 | 0.100 |
Why?
|
| Radiation Pneumonitis | 3 | 2018 | 313 | 0.100 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 1956 | 0.100 |
Why?
|
| Immunoglobulin G | 2 | 2015 | 1129 | 0.100 |
Why?
|
| Tetrahydronaphthalenes | 2 | 2012 | 114 | 0.100 |
Why?
|
| Aminoacridines | 5 | 1986 | 23 | 0.100 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2024 | 500 | 0.100 |
Why?
|
| Salvage Therapy | 3 | 2015 | 2123 | 0.100 |
Why?
|
| Lymphatic Metastasis | 9 | 2012 | 4963 | 0.100 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2011 | 84 | 0.100 |
Why?
|
| Catalytic Domain | 1 | 2012 | 305 | 0.090 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2023 | 1097 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 2 | 2008 | 1586 | 0.090 |
Why?
|
| Biological Availability | 2 | 2011 | 225 | 0.090 |
Why?
|
| Tumor Microenvironment | 4 | 2024 | 3035 | 0.090 |
Why?
|
| Mitoxantrone | 8 | 1995 | 227 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2012 | 266 | 0.090 |
Why?
|
| Leukopenia | 6 | 1985 | 152 | 0.090 |
Why?
|
| Carcinoma, Small Cell | 2 | 2003 | 427 | 0.090 |
Why?
|
| Brain Neoplasms | 5 | 2023 | 4958 | 0.090 |
Why?
|
| Radiography, Thoracic | 1 | 2013 | 477 | 0.090 |
Why?
|
| Tumor Stem Cell Assay | 3 | 1985 | 230 | 0.090 |
Why?
|
| Piperidines | 2 | 2013 | 1100 | 0.090 |
Why?
|
| Papillomavirus Infections | 1 | 2019 | 999 | 0.090 |
Why?
|
| Trigeminal Nerve Diseases | 1 | 2009 | 14 | 0.080 |
Why?
|
| Thyroid Neoplasms | 1 | 2020 | 1894 | 0.080 |
Why?
|
| Tongue Neoplasms | 1 | 2011 | 253 | 0.080 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2011 | 350 | 0.080 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2009 | 47 | 0.080 |
Why?
|
| Etoposide | 5 | 2010 | 907 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 2 | 2015 | 4048 | 0.080 |
Why?
|
| Facial Neoplasms | 1 | 2009 | 77 | 0.080 |
Why?
|
| Genes, ras | 1 | 2012 | 679 | 0.080 |
Why?
|
| Colony-Forming Units Assay | 3 | 1985 | 253 | 0.080 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2012 | 678 | 0.080 |
Why?
|
| Meningeal Neoplasms | 5 | 1982 | 473 | 0.080 |
Why?
|
| Fatigue | 2 | 2017 | 1275 | 0.080 |
Why?
|
| Bronchial Neoplasms | 2 | 1978 | 82 | 0.080 |
Why?
|
| Capsules | 1 | 2007 | 54 | 0.070 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2009 | 231 | 0.070 |
Why?
|
| Salivary Ducts | 1 | 2007 | 55 | 0.070 |
Why?
|
| Adenocarcinoma, Sebaceous | 1 | 2008 | 66 | 0.070 |
Why?
|
| Menopause | 10 | 1985 | 160 | 0.070 |
Why?
|
| Castration | 8 | 1983 | 122 | 0.070 |
Why?
|
| Proton Therapy | 1 | 2018 | 1637 | 0.070 |
Why?
|
| Environment, Controlled | 1 | 1987 | 22 | 0.070 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2008 | 100 | 0.070 |
Why?
|
| Hypertriglyceridemia | 1 | 2008 | 115 | 0.070 |
Why?
|
| Parotid Neoplasms | 1 | 2008 | 150 | 0.070 |
Why?
|
| Quality of Life | 3 | 2017 | 4761 | 0.070 |
Why?
|
| Dyspnea | 2 | 2022 | 420 | 0.070 |
Why?
|
| Infusions, Intravenous | 7 | 2005 | 1437 | 0.070 |
Why?
|
| Precision Medicine | 2 | 2013 | 1207 | 0.070 |
Why?
|
| Drug Therapy | 2 | 2007 | 205 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2011 | 676 | 0.070 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2018 | 2178 | 0.070 |
Why?
|
| Dendritic Cells | 1 | 2013 | 1110 | 0.070 |
Why?
|
| Thiazoles | 1 | 2010 | 723 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2019 | 9470 | 0.070 |
Why?
|
| Melanoma | 2 | 2023 | 5595 | 0.070 |
Why?
|
| Pyrimidines | 3 | 2020 | 3669 | 0.070 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2006 | 67 | 0.060 |
Why?
|
| Pleural Effusion | 5 | 1985 | 228 | 0.060 |
Why?
|
| Diarrhea | 1 | 2009 | 716 | 0.060 |
Why?
|
| Hypercalcemia | 3 | 1981 | 145 | 0.060 |
Why?
|
| Forecasting | 1 | 2008 | 702 | 0.060 |
Why?
|
| Vinca Alkaloids | 1 | 1985 | 8 | 0.060 |
Why?
|
| Mitolactol | 2 | 1984 | 7 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2008 | 6764 | 0.060 |
Why?
|
| Molecular Epidemiology | 1 | 2006 | 247 | 0.060 |
Why?
|
| Stomach Neoplasms | 1 | 2017 | 2331 | 0.060 |
Why?
|
| Neoplasm Transplantation | 1 | 2008 | 1553 | 0.060 |
Why?
|
| Fever | 4 | 1984 | 521 | 0.060 |
Why?
|
| Heart Failure | 9 | 1985 | 2330 | 0.060 |
Why?
|
| Immunohistochemistry | 5 | 2018 | 7655 | 0.060 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2022 | 565 | 0.060 |
Why?
|
| Anthraquinones | 4 | 1985 | 28 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2007 | 2271 | 0.060 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2018 | 2457 | 0.060 |
Why?
|
| Bone Marrow Diseases | 2 | 1984 | 186 | 0.060 |
Why?
|
| Amifostine | 1 | 2004 | 99 | 0.060 |
Why?
|
| Esophageal Neoplasms | 1 | 2017 | 3240 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2024 | 262 | 0.060 |
Why?
|
| Radiation-Protective Agents | 1 | 2004 | 129 | 0.060 |
Why?
|
| Remission, Spontaneous | 13 | 1980 | 125 | 0.060 |
Why?
|
| Paralysis | 1 | 1983 | 54 | 0.050 |
Why?
|
| Estradiol | 2 | 1985 | 827 | 0.050 |
Why?
|
| Peptichemio | 5 | 1984 | 12 | 0.050 |
Why?
|
| Tumor Burden | 3 | 2019 | 2033 | 0.050 |
Why?
|
| Mastectomy | 9 | 1986 | 1553 | 0.050 |
Why?
|
| DEAE-Dextran | 1 | 1983 | 6 | 0.050 |
Why?
|
| Vincristine | 8 | 1985 | 1583 | 0.050 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 1986 | 557 | 0.050 |
Why?
|
| Skull Neoplasms | 1 | 1983 | 68 | 0.050 |
Why?
|
| Injections, Subcutaneous | 3 | 2003 | 342 | 0.050 |
Why?
|
| Glaucarubin | 1 | 1982 | 2 | 0.050 |
Why?
|
| Quassins | 1 | 1982 | 4 | 0.050 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2013 | 1386 | 0.050 |
Why?
|
| Dextrans | 1 | 1983 | 98 | 0.050 |
Why?
|
| Lymphocytes | 3 | 2020 | 1275 | 0.050 |
Why?
|
| Cranial Nerve Diseases | 1 | 1983 | 77 | 0.050 |
Why?
|
| HLA-A Antigens | 1 | 2023 | 105 | 0.050 |
Why?
|
| Age Factors | 5 | 2019 | 5457 | 0.050 |
Why?
|
| Phenanthrenes | 1 | 1982 | 43 | 0.050 |
Why?
|
| Thinness | 1 | 2023 | 79 | 0.050 |
Why?
|
| Induction Chemotherapy | 2 | 2019 | 670 | 0.050 |
Why?
|
| Valproic Acid | 1 | 2023 | 272 | 0.050 |
Why?
|
| Daunorubicin | 2 | 1984 | 314 | 0.050 |
Why?
|
| Arthrogryposis | 1 | 2022 | 34 | 0.050 |
Why?
|
| Genomics | 2 | 2024 | 2835 | 0.050 |
Why?
|
| Biological Therapy | 1 | 2002 | 57 | 0.050 |
Why?
|
| Prospective Studies | 8 | 2023 | 13414 | 0.050 |
Why?
|
| Recurrence | 5 | 2023 | 4878 | 0.050 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1984 | 402 | 0.050 |
Why?
|
| Area Under Curve | 2 | 2015 | 729 | 0.050 |
Why?
|
| Vomiting | 7 | 1984 | 361 | 0.050 |
Why?
|
| Diazoxide | 1 | 1980 | 9 | 0.050 |
Why?
|
| Neutropenia | 4 | 2010 | 1006 | 0.050 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2023 | 256 | 0.050 |
Why?
|
| Radiotherapy Dosage | 5 | 2015 | 4019 | 0.050 |
Why?
|
| Hematoma, Subdural | 1 | 1980 | 30 | 0.050 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2003 | 285 | 0.050 |
Why?
|
| Random Allocation | 7 | 1987 | 741 | 0.050 |
Why?
|
| Ifosfamide | 3 | 2011 | 358 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2018 | 2313 | 0.050 |
Why?
|
| Radiotherapy, High-Energy | 2 | 1981 | 303 | 0.050 |
Why?
|
| Deoxycytidine | 2 | 2005 | 1389 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2023 | 450 | 0.050 |
Why?
|
| Ischemia | 1 | 2023 | 400 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2013 | 9042 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2024 | 1126 | 0.040 |
Why?
|
| Immune Complex Diseases | 1 | 1980 | 12 | 0.040 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2002 | 172 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 1557 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 4 | 2002 | 742 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2023 | 383 | 0.040 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 1980 | 144 | 0.040 |
Why?
|
| Adolescent | 7 | 2023 | 32767 | 0.040 |
Why?
|
| Animals | 8 | 2024 | 61956 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2012 | 7238 | 0.040 |
Why?
|
| Glomerulonephritis | 1 | 1980 | 109 | 0.040 |
Why?
|
| Infusions, Parenteral | 8 | 1992 | 197 | 0.040 |
Why?
|
| Heart Diseases | 1 | 1985 | 724 | 0.040 |
Why?
|
| Leucovorin | 4 | 1984 | 345 | 0.040 |
Why?
|
| Liver Diseases | 2 | 1983 | 602 | 0.040 |
Why?
|
| Amenorrhea | 1 | 1978 | 30 | 0.040 |
Why?
|
| Pulmonary Fibrosis | 1 | 1980 | 175 | 0.040 |
Why?
|
| Nails | 1 | 1978 | 36 | 0.040 |
Why?
|
| Cytarabine | 1 | 1985 | 2014 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2023 | 1824 | 0.040 |
Why?
|
| Pigmentation Disorders | 1 | 1978 | 42 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2015 | 2353 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2019 | 751 | 0.040 |
Why?
|
| Interleukin-2 | 2 | 1992 | 889 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2020 | 374 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 1980 | 520 | 0.040 |
Why?
|
| Alopecia | 5 | 1984 | 123 | 0.040 |
Why?
|
| Pituitary Gland | 1 | 1978 | 151 | 0.040 |
Why?
|
| Social Participation | 1 | 2017 | 28 | 0.040 |
Why?
|
| Sensation Disorders | 1 | 2017 | 35 | 0.040 |
Why?
|
| Thiotepa | 2 | 1995 | 132 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2020 | 689 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2022 | 1516 | 0.040 |
Why?
|
| Receptors, Progesterone | 3 | 2012 | 1604 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 1995 | 7044 | 0.040 |
Why?
|
| Antigens, CD19 | 1 | 2020 | 584 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 4372 | 0.040 |
Why?
|
| Drug Resistance | 5 | 1985 | 610 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 1982 | 1958 | 0.030 |
Why?
|
| Hematologic Diseases | 2 | 2010 | 255 | 0.030 |
Why?
|
| Prednisone | 4 | 1984 | 1034 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2024 | 1903 | 0.030 |
Why?
|
| Lymph Nodes | 3 | 2019 | 3077 | 0.030 |
Why?
|
| Mice | 6 | 2024 | 35600 | 0.030 |
Why?
|
| Anthracenes | 4 | 1986 | 47 | 0.030 |
Why?
|
| Leukocyte Count | 5 | 1987 | 735 | 0.030 |
Why?
|
| Tissue Preservation | 1 | 1995 | 27 | 0.030 |
Why?
|
| Cell Count | 1 | 1997 | 512 | 0.030 |
Why?
|
| Carmustine | 1 | 1995 | 225 | 0.030 |
Why?
|
| Anesthesia, Local | 1 | 1995 | 64 | 0.030 |
Why?
|
| Young Adult | 4 | 2018 | 22251 | 0.030 |
Why?
|
| Mitomycin | 3 | 1985 | 213 | 0.030 |
Why?
|
| Melphalan | 3 | 1982 | 879 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 823 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2023 | 2232 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 1980 | 1723 | 0.030 |
Why?
|
| Blood Cell Count | 7 | 1983 | 233 | 0.030 |
Why?
|
| Cell Line, Tumor | 3 | 2018 | 14849 | 0.030 |
Why?
|
| Lectins | 2 | 1974 | 148 | 0.030 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 1985 | 49 | 0.030 |
Why?
|
| Ovary | 1 | 1978 | 688 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 1655 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2003 | 4000 | 0.030 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1979 | 690 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2019 | 797 | 0.030 |
Why?
|
| Cyclohexanes | 2 | 2004 | 41 | 0.030 |
Why?
|
| Enterotoxins | 1 | 1974 | 122 | 0.030 |
Why?
|
| Risk | 5 | 1987 | 1939 | 0.030 |
Why?
|
| Lipocalins | 1 | 2013 | 54 | 0.030 |
Why?
|
| Interleukin-9 | 1 | 2013 | 37 | 0.030 |
Why?
|
| Transcription Factors | 2 | 2023 | 5438 | 0.030 |
Why?
|
| Megestrol Acetate | 2 | 1983 | 30 | 0.030 |
Why?
|
| Acute-Phase Proteins | 1 | 2013 | 85 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 1823 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2012 | 4942 | 0.030 |
Why?
|
| Lipocalin-2 | 1 | 2013 | 77 | 0.030 |
Why?
|
| Genes, erbB-1 | 1 | 2013 | 104 | 0.030 |
Why?
|
| Everolimus | 1 | 2015 | 436 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2015 | 307 | 0.030 |
Why?
|
| Agranulocytosis | 5 | 2004 | 83 | 0.030 |
Why?
|
| Sleep Stages | 2 | 1982 | 82 | 0.030 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2013 | 210 | 0.030 |
Why?
|
| Outpatients | 1 | 1995 | 463 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 2359 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2013 | 453 | 0.020 |
Why?
|
| Biomarkers | 1 | 2023 | 5051 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2023 | 3438 | 0.020 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2011 | 84 | 0.020 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2015 | 340 | 0.020 |
Why?
|
| Amsacrine | 4 | 1986 | 63 | 0.020 |
Why?
|
| Hypotension | 2 | 1985 | 232 | 0.020 |
Why?
|
| Half-Life | 2 | 2010 | 269 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2011 | 77 | 0.020 |
Why?
|
| Sirolimus | 1 | 2016 | 831 | 0.020 |
Why?
|
| Glossectomy | 1 | 2011 | 43 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2020 | 1546 | 0.020 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1991 | 55 | 0.020 |
Why?
|
| Aspartic Acid | 1 | 2012 | 136 | 0.020 |
Why?
|
| Valine | 1 | 2012 | 180 | 0.020 |
Why?
|
| Lentivirus | 1 | 2012 | 164 | 0.020 |
Why?
|
| Pain Measurement | 1 | 1995 | 1016 | 0.020 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 861 | 0.020 |
Why?
|
| Stomatitis | 2 | 1984 | 193 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2011 | 153 | 0.020 |
Why?
|
| Cell Line | 3 | 1985 | 5338 | 0.020 |
Why?
|
| Levamisole | 3 | 1979 | 13 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2011 | 126 | 0.020 |
Why?
|
| Cysteine | 1 | 2012 | 214 | 0.020 |
Why?
|
| Nitrosourea Compounds | 2 | 1982 | 14 | 0.020 |
Why?
|
| Asparaginase | 3 | 1981 | 196 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2012 | 396 | 0.020 |
Why?
|
| Nervous System Neoplasms | 2 | 1980 | 35 | 0.020 |
Why?
|
| Genotype | 1 | 2019 | 4252 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 589 | 0.020 |
Why?
|
| Neck Dissection | 1 | 2011 | 294 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 1995 | 2067 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 625 | 0.020 |
Why?
|
| Obesity | 1 | 2023 | 2904 | 0.020 |
Why?
|
| Gene Expression Profiling | 2 | 2012 | 5149 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2012 | 895 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2013 | 766 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 4960 | 0.020 |
Why?
|
| Ovarian Neoplasms | 2 | 1984 | 4795 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2010 | 179 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 1075 | 0.020 |
Why?
|
| Diagnostic Errors | 2 | 2008 | 518 | 0.020 |
Why?
|
| Texas | 4 | 2010 | 6449 | 0.020 |
Why?
|
| Cheek | 1 | 2009 | 56 | 0.020 |
Why?
|
| Glycine | 1 | 2012 | 322 | 0.020 |
Why?
|
| Radiotherapy, Conformal | 1 | 2015 | 898 | 0.020 |
Why?
|
| Lung | 1 | 2020 | 3298 | 0.020 |
Why?
|
| Clone Cells | 3 | 1985 | 591 | 0.020 |
Why?
|
| Skin Diseases | 2 | 1982 | 366 | 0.020 |
Why?
|
| Moloney murine leukemia virus | 1 | 1969 | 36 | 0.020 |
Why?
|
| Bacterial Infections | 2 | 1984 | 510 | 0.020 |
Why?
|
| Rats | 1 | 2018 | 6441 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2013 | 1379 | 0.020 |
Why?
|
| Sarcoma, Experimental | 1 | 1969 | 68 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 442 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 1312 | 0.020 |
Why?
|
| Pain | 1 | 2017 | 1694 | 0.020 |
Why?
|
| Proteome | 1 | 2012 | 571 | 0.020 |
Why?
|
| Androgens | 2 | 1983 | 506 | 0.020 |
Why?
|
| Chalazion | 1 | 2008 | 2 | 0.020 |
Why?
|
| Prolactin | 2 | 1978 | 169 | 0.020 |
Why?
|
| Vindesine | 2 | 1985 | 11 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 3444 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 1983 | 625 | 0.020 |
Why?
|
| Estrogens | 2 | 1983 | 805 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 1992 | 959 | 0.020 |
Why?
|
| Triazines | 2 | 1979 | 121 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2011 | 1691 | 0.020 |
Why?
|
| Co-Repressor Proteins | 1 | 2007 | 120 | 0.020 |
Why?
|
| Cells, Cultured | 3 | 1985 | 5694 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2010 | 1810 | 0.020 |
Why?
|
| Premedication | 1 | 1987 | 133 | 0.020 |
Why?
|
| Estrogen Receptor beta | 1 | 2007 | 149 | 0.020 |
Why?
|
| Soft Tissue Neoplasms | 3 | 1984 | 927 | 0.020 |
Why?
|
| Palliative Care | 3 | 1982 | 2178 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2012 | 1857 | 0.020 |
Why?
|
| Risk Factors | 2 | 2018 | 17888 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 1985 | 497 | 0.020 |
Why?
|
| Drug Eruptions | 2 | 2005 | 271 | 0.020 |
Why?
|
| Benzamides | 1 | 2011 | 1879 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2013 | 7783 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 3 | 1981 | 452 | 0.020 |
Why?
|
| Pyrrolidines | 1 | 1986 | 113 | 0.020 |
Why?
|
| Glutamates | 1 | 2005 | 134 | 0.020 |
Why?
|
| Rhabdomyosarcoma | 1 | 1969 | 342 | 0.020 |
Why?
|
| DNA | 1 | 1974 | 3050 | 0.020 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2005 | 125 | 0.020 |
Why?
|
| Guanine | 1 | 2005 | 157 | 0.020 |
Why?
|
| Proteomics | 1 | 2012 | 1427 | 0.020 |
Why?
|
| Injections, Intraventricular | 2 | 1982 | 125 | 0.020 |
Why?
|
| Estrogen Antagonists | 1 | 1986 | 188 | 0.020 |
Why?
|
| Germanium | 1 | 1984 | 7 | 0.020 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2008 | 290 | 0.020 |
Why?
|
| Neoplasm Regression, Spontaneous | 2 | 1978 | 39 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 7381 | 0.010 |
Why?
|
| Spiro Compounds | 1 | 1984 | 59 | 0.010 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 1985 | 63 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 2069 | 0.010 |
Why?
|
| Immunity, Cellular | 2 | 1980 | 440 | 0.010 |
Why?
|
| Carubicin | 1 | 1984 | 2 | 0.010 |
Why?
|
| United States | 3 | 2015 | 15861 | 0.010 |
Why?
|
| Amphotericin B | 2 | 1978 | 298 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 2005 | 334 | 0.010 |
Why?
|
| Anemia | 1 | 2010 | 728 | 0.010 |
Why?
|
| Intercalating Agents | 1 | 1983 | 32 | 0.010 |
Why?
|
| Eye Enucleation | 1 | 2003 | 87 | 0.010 |
Why?
|
| Cell Division | 2 | 1985 | 2657 | 0.010 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2003 | 175 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2014 | 17061 | 0.010 |
Why?
|
| Propionibacterium acnes | 2 | 1980 | 24 | 0.010 |
Why?
|
| Organometallic Compounds | 1 | 1984 | 209 | 0.010 |
Why?
|
| Azirines | 1 | 1983 | 5 | 0.010 |
Why?
|
| Aziridines | 1 | 1983 | 19 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2005 | 572 | 0.010 |
Why?
|
| Blood Chemical Analysis | 1 | 1983 | 113 | 0.010 |
Why?
|
| Axilla | 2 | 1983 | 939 | 0.010 |
Why?
|
| Specimen Handling | 1 | 1985 | 307 | 0.010 |
Why?
|
| Tegafur | 2 | 1979 | 51 | 0.010 |
Why?
|
| Diethylstilbestrol | 1 | 1983 | 165 | 0.010 |
Why?
|
| Cardiomyopathies | 2 | 1985 | 552 | 0.010 |
Why?
|
| Dizziness | 1 | 1982 | 42 | 0.010 |
Why?
|
| Benzoquinones | 1 | 1983 | 110 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2004 | 749 | 0.010 |
Why?
|
| Skin Tests | 2 | 1981 | 101 | 0.010 |
Why?
|
| Interphase | 1 | 1982 | 156 | 0.010 |
Why?
|
| Orbit | 1 | 2003 | 209 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 6177 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2007 | 2090 | 0.010 |
Why?
|
| Receptors, Androgen | 1 | 2007 | 854 | 0.010 |
Why?
|
| Thyrotropin-Releasing Hormone | 2 | 1978 | 16 | 0.010 |
Why?
|
| Injections, Spinal | 1 | 1982 | 273 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 1983 | 4831 | 0.010 |
Why?
|
| Mitoguazone | 1 | 1981 | 10 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 2197 | 0.010 |
Why?
|
| Cobalt Radioisotopes | 1 | 1981 | 41 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1983 | 702 | 0.010 |
Why?
|
| Breast Diseases | 2 | 1980 | 200 | 0.010 |
Why?
|
| Cytokines | 1 | 2010 | 2825 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2011 | 6224 | 0.010 |
Why?
|
| Guanidines | 1 | 1981 | 61 | 0.010 |
Why?
|
| Subdural Space | 1 | 1980 | 8 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2007 | 1624 | 0.010 |
Why?
|
| Hernia | 1 | 1980 | 45 | 0.010 |
Why?
|
| Edema | 1 | 1982 | 262 | 0.010 |
Why?
|
| Aneuploidy | 1 | 1982 | 382 | 0.010 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 1980 | 40 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1983 | 1571 | 0.010 |
Why?
|
| Heart | 3 | 1986 | 1195 | 0.010 |
Why?
|
| Altretamine | 1 | 1979 | 4 | 0.010 |
Why?
|
| Radioisotope Teletherapy | 1 | 1979 | 11 | 0.010 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 1980 | 74 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 1985 | 608 | 0.010 |
Why?
|
| Diabetes Insipidus | 1 | 1979 | 24 | 0.010 |
Why?
|
| Electrons | 1 | 1981 | 188 | 0.010 |
Why?
|
| Skin Ulcer | 1 | 1980 | 74 | 0.010 |
Why?
|
| Trichothecenes | 1 | 1979 | 6 | 0.010 |
Why?
|
| Bacterial Vaccines | 1 | 1980 | 118 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1983 | 2315 | 0.010 |
Why?
|
| Alleles | 1 | 2006 | 2600 | 0.010 |
Why?
|
| Urogenital Neoplasms | 1 | 1980 | 115 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1979 | 123 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1980 | 707 | 0.010 |
Why?
|
| Prevalence | 1 | 2007 | 3404 | 0.010 |
Why?
|
| Interferons | 1 | 1980 | 299 | 0.010 |
Why?
|
| Child | 2 | 2014 | 30559 | 0.010 |
Why?
|
| Biopsy | 3 | 1982 | 3484 | 0.010 |
Why?
|
| Thyrotropin | 1 | 1978 | 124 | 0.010 |
Why?
|
| Lomustine | 1 | 1978 | 42 | 0.010 |
Why?
|
| Heart Neoplasms | 1 | 1980 | 209 | 0.010 |
Why?
|
| Luteinizing Hormone | 1 | 1978 | 165 | 0.010 |
Why?
|
| Sarcoma | 3 | 1978 | 1839 | 0.010 |
Why?
|
| Paraplegia | 1 | 1978 | 99 | 0.010 |
Why?
|
| Follicle Stimulating Hormone | 1 | 1978 | 224 | 0.010 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 1978 | 169 | 0.010 |
Why?
|
| Dacarbazine | 2 | 1978 | 502 | 0.010 |
Why?
|
| Leukemia | 1 | 1986 | 1719 | 0.010 |
Why?
|
| Tritium | 2 | 1974 | 268 | 0.010 |
Why?
|
| Thymidine | 2 | 1974 | 167 | 0.010 |
Why?
|
| Triazenes | 1 | 1976 | 2 | 0.010 |
Why?
|
| Folic Acid Antagonists | 1 | 1976 | 48 | 0.010 |
Why?
|
| Phenotype | 1 | 2007 | 6509 | 0.010 |
Why?
|
| Dactinomycin | 1 | 1976 | 163 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2002 | 1347 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1982 | 3045 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1980 | 727 | 0.010 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2002 | 1458 | 0.010 |
Why?
|
| Brain Diseases | 1 | 1978 | 412 | 0.010 |
Why?
|
| Puromycin | 1 | 1974 | 18 | 0.010 |
Why?
|
| Concanavalin A | 1 | 1974 | 63 | 0.010 |
Why?
|
| Cytidine | 1 | 1974 | 24 | 0.010 |
Why?
|
| Peritoneal Neoplasms | 1 | 1981 | 859 | 0.010 |
Why?
|
| Pneumonia | 1 | 1980 | 796 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1987 | 3187 | 0.010 |
Why?
|
| Phosphotransferases | 1 | 1974 | 82 | 0.010 |
Why?
|
| Leiomyosarcoma | 1 | 1976 | 253 | 0.010 |
Why?
|
| Granulocytes | 2 | 1987 | 244 | 0.010 |
Why?
|
| Staphylococcus | 1 | 1974 | 98 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 1974 | 257 | 0.010 |
Why?
|
| Uridine | 1 | 1974 | 72 | 0.010 |
Why?
|
| Telephone | 1 | 1973 | 160 | 0.010 |
Why?
|
| Electrocardiography | 1 | 1979 | 1154 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 7895 | 0.010 |
Why?
|
| Candidiasis, Cutaneous | 1 | 1971 | 4 | 0.010 |
Why?
|
| Blood Protein Disorders | 1 | 1971 | 2 | 0.010 |
Why?
|
| gamma-Globulins | 1 | 1971 | 19 | 0.010 |
Why?
|
| Lymphoma | 1 | 1980 | 1519 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1971 | 107 | 0.010 |
Why?
|
| Education, Medical, Continuing | 1 | 1973 | 231 | 0.010 |
Why?
|
| Health Education | 1 | 1973 | 303 | 0.010 |
Why?
|
| Hypertension | 1 | 1980 | 1591 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 1971 | 286 | 0.010 |
Why?
|
| Plasma Cells | 1 | 1971 | 197 | 0.010 |
Why?
|
| Heavy Chain Disease | 1 | 1970 | 1 | 0.010 |
Why?
|
| Multiple Myeloma | 2 | 1980 | 2328 | 0.010 |
Why?
|
| Injections, Intravenous | 2 | 1981 | 591 | 0.010 |
Why?
|
| Platelet Count | 2 | 1981 | 492 | 0.010 |
Why?
|
| Kinetics | 2 | 1984 | 2220 | 0.010 |
Why?
|
| Brain | 1 | 1982 | 4208 | 0.010 |
Why?
|
| Infant | 1 | 1984 | 13999 | 0.000 |
Why?
|
| Organ Size | 1 | 1969 | 692 | 0.000 |
Why?
|
| Bence Jones Protein | 2 | 1980 | 11 | 0.000 |
Why?
|
| Spleen | 1 | 1969 | 726 | 0.000 |
Why?
|
| Recombinant Proteins | 1 | 1991 | 3028 | 0.000 |
Why?
|
| Phlebitis | 1 | 1984 | 9 | 0.000 |
Why?
|
| Leukocytes | 2 | 1980 | 421 | 0.000 |
Why?
|
| Animals, Newborn | 1 | 1969 | 1368 | 0.000 |
Why?
|
| Central Nervous System Diseases | 1 | 1984 | 134 | 0.000 |
Why?
|
| Mustard Compounds | 1 | 1982 | 9 | 0.000 |
Why?
|
| Immunoelectrophoresis | 2 | 1971 | 27 | 0.000 |
Why?
|
| Myeloma Proteins | 1 | 1980 | 27 | 0.000 |
Why?
|
| Injections, Intramuscular | 1 | 1981 | 247 | 0.000 |
Why?
|
| Pseudomonas | 1 | 1980 | 22 | 0.000 |
Why?
|
| Sella Turcica | 1 | 1979 | 23 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1986 | 1568 | 0.000 |
Why?
|
| Vasopressins | 1 | 1979 | 63 | 0.000 |
Why?
|
| Digestive System | 1 | 1979 | 121 | 0.000 |
Why?
|
| Fusarium | 1 | 1979 | 57 | 0.000 |
Why?
|
| Monitoring, Physiologic | 1 | 1982 | 512 | 0.000 |
Why?
|
| Triiodothyronine | 1 | 1978 | 84 | 0.000 |
Why?
|
| Angina Pectoris | 1 | 1978 | 67 | 0.000 |
Why?
|
| Thyroxine | 1 | 1978 | 114 | 0.000 |
Why?
|
| Pruritus | 1 | 1978 | 90 | 0.000 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1978 | 127 | 0.000 |
Why?
|
| Lymphatic Diseases | 1 | 1978 | 127 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1980 | 1121 | 0.000 |
Why?
|
| Cell Survival | 1 | 1984 | 3063 | 0.000 |
Why?
|
| Pituitary Neoplasms | 1 | 1979 | 216 | 0.000 |
Why?
|
| Central Nervous System | 1 | 1979 | 451 | 0.000 |
Why?
|
| Registries | 1 | 1985 | 2211 | 0.000 |
Why?
|
| Thyroid Gland | 1 | 1978 | 366 | 0.000 |
Why?
|
| Myocardium | 1 | 1982 | 1232 | 0.000 |
Why?
|
| Myeloproliferative Disorders | 1 | 1984 | 882 | 0.000 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1979 | 401 | 0.000 |
Why?
|
| Thoracic Neoplasms | 1 | 1979 | 363 | 0.000 |
Why?
|
| Sex Factors | 1 | 1980 | 2184 | 0.000 |
Why?
|
| Syndrome | 1 | 1978 | 1407 | 0.000 |
Why?
|
| Body Weight | 1 | 1979 | 1307 | 0.000 |
Why?
|
| Dogs | 1 | 1976 | 1160 | 0.000 |
Why?
|
| District of Columbia | 1 | 1973 | 19 | 0.000 |
Why?
|
| Alabama | 1 | 1973 | 46 | 0.000 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1973 | 197 | 0.000 |
Why?
|
| Peptide Biosynthesis | 1 | 1971 | 26 | 0.000 |
Why?
|
| Candida albicans | 1 | 1971 | 186 | 0.000 |
Why?
|
| Immunodiffusion | 1 | 1970 | 30 | 0.000 |
Why?
|
| Immunochemistry | 1 | 1970 | 61 | 0.000 |
Why?
|
| Haplorhini | 1 | 1970 | 152 | 0.000 |
Why?
|
| Carbohydrates | 1 | 1970 | 55 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1970 | 721 | 0.000 |
Why?
|
| Antigens | 1 | 1970 | 281 | 0.000 |
Why?
|
| Mitosis | 1 | 1971 | 681 | 0.000 |
Why?
|
| Rabbits | 1 | 1970 | 1028 | 0.000 |
Why?
|
| Referral and Consultation | 1 | 1973 | 931 | 0.000 |
Why?
|
| Epitopes | 1 | 1970 | 707 | 0.000 |
Why?
|
| Communication | 1 | 1973 | 839 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1971 | 4567 | 0.000 |
Why?
|
| Peptides | 1 | 1970 | 1504 | 0.000 |
Why?
|
| Asthma | 1 | 1971 | 895 | 0.000 |
Why?
|